Effect of Trospium Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial

Research output: Contribution to journalArticle

  • 1 Citations

Abstract

Objectives This study aimed to investigate the effect of trospium chloride on cognitive function in postmenopausal women treated for overactive bladder (OAB). Methods Randomized double-blind placebo-controlled trial conducted from April 2013 to April 2015. Women aged 50 years or older seeking treatment for OAB were randomized to either trospium chloride XR 60 mg daily or placebo. Baseline cognitive function was assessed via Hopkins Verbal Learning Test-Revised (HVLT-R), Mini Mental Status Exam, Mini Mental Status X, Digit Span, Trails A, Trails B, and Epworth Sleepiness Scale. Cognitive function was reassessed at week 1 and week 4. A priori power analysis determined that 21 subjects were needed per group. Results Although 59 women were enrolled and randomized (28 trospium and 31 placebo), 45 completed assessment (21 trospium and 24 placebo). Mean age was 68 years, 78% were white, and 44% had previously taken OAB medication. For the primary outcome, there was no difference in HVLT-R total score between trospium and placebo groups at week 4 (P = 0.29). There were also no differences based on the other cognitive tests. There was a correlation between age and the following week-4 tests: HVLT-R total score (r =-0.3, P = 0.02), HVLT-R total recall subscale (r =-0.4, P = 0.007), Trails A (r = 0.4, P = 0.002), and Trails B (r = 0.4, P = 0.004). A linear regression model found that HVLT-R total score decreased by 0.372 points for each increased year of age. Conclusions In women aged 50 years and older, there were no changes in cognitive function between those taking trospium and placebo. Cognitive function was correlated with age.

LanguageEnglish (US)
Pages118-123
Number of pages6
JournalFemale Pelvic Medicine and Reconstructive Surgery
Volume23
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Verbal Learning
Cognition
Placebos
Overactive Urinary Bladder
Linear Models
Double-Blind Method
trospium chloride

Keywords

  • anticholinergic
  • cognitive function
  • overactive bladder

ASJC Scopus subject areas

  • Surgery
  • Obstetrics and Gynecology
  • Urology

Cite this

@article{ffa0f389a534474792b70c14e9d79213,
title = "Effect of Trospium Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial",
abstract = "Objectives This study aimed to investigate the effect of trospium chloride on cognitive function in postmenopausal women treated for overactive bladder (OAB). Methods Randomized double-blind placebo-controlled trial conducted from April 2013 to April 2015. Women aged 50 years or older seeking treatment for OAB were randomized to either trospium chloride XR 60 mg daily or placebo. Baseline cognitive function was assessed via Hopkins Verbal Learning Test-Revised (HVLT-R), Mini Mental Status Exam, Mini Mental Status X, Digit Span, Trails A, Trails B, and Epworth Sleepiness Scale. Cognitive function was reassessed at week 1 and week 4. A priori power analysis determined that 21 subjects were needed per group. Results Although 59 women were enrolled and randomized (28 trospium and 31 placebo), 45 completed assessment (21 trospium and 24 placebo). Mean age was 68 years, 78{\%} were white, and 44{\%} had previously taken OAB medication. For the primary outcome, there was no difference in HVLT-R total score between trospium and placebo groups at week 4 (P = 0.29). There were also no differences based on the other cognitive tests. There was a correlation between age and the following week-4 tests: HVLT-R total score (r =-0.3, P = 0.02), HVLT-R total recall subscale (r =-0.4, P = 0.007), Trails A (r = 0.4, P = 0.002), and Trails B (r = 0.4, P = 0.004). A linear regression model found that HVLT-R total score decreased by 0.372 points for each increased year of age. Conclusions In women aged 50 years and older, there were no changes in cognitive function between those taking trospium and placebo. Cognitive function was correlated with age.",
keywords = "anticholinergic, cognitive function, overactive bladder",
author = "Geller, {Elizabeth J.} and Dumond, {Julie B.} and Bowling, {J. Michael} and Khandelwal, {Christine M.} and Wu, {Jennifer M.} and Jan Busby-Whitehead and Kaufer, {Daniel I.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1097/SPV.0000000000000374",
language = "English (US)",
volume = "23",
pages = "118--123",
journal = "Female Pelvic Medicine and Reconstructive Surgery",
issn = "2151-8378",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effect of Trospium Chloride on Cognitive Function in Women Aged 50 and Older

T2 - Female Pelvic Medicine and Reconstructive Surgery

AU - Geller,Elizabeth J.

AU - Dumond,Julie B.

AU - Bowling,J. Michael

AU - Khandelwal,Christine M.

AU - Wu,Jennifer M.

AU - Busby-Whitehead,Jan

AU - Kaufer,Daniel I.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objectives This study aimed to investigate the effect of trospium chloride on cognitive function in postmenopausal women treated for overactive bladder (OAB). Methods Randomized double-blind placebo-controlled trial conducted from April 2013 to April 2015. Women aged 50 years or older seeking treatment for OAB were randomized to either trospium chloride XR 60 mg daily or placebo. Baseline cognitive function was assessed via Hopkins Verbal Learning Test-Revised (HVLT-R), Mini Mental Status Exam, Mini Mental Status X, Digit Span, Trails A, Trails B, and Epworth Sleepiness Scale. Cognitive function was reassessed at week 1 and week 4. A priori power analysis determined that 21 subjects were needed per group. Results Although 59 women were enrolled and randomized (28 trospium and 31 placebo), 45 completed assessment (21 trospium and 24 placebo). Mean age was 68 years, 78% were white, and 44% had previously taken OAB medication. For the primary outcome, there was no difference in HVLT-R total score between trospium and placebo groups at week 4 (P = 0.29). There were also no differences based on the other cognitive tests. There was a correlation between age and the following week-4 tests: HVLT-R total score (r =-0.3, P = 0.02), HVLT-R total recall subscale (r =-0.4, P = 0.007), Trails A (r = 0.4, P = 0.002), and Trails B (r = 0.4, P = 0.004). A linear regression model found that HVLT-R total score decreased by 0.372 points for each increased year of age. Conclusions In women aged 50 years and older, there were no changes in cognitive function between those taking trospium and placebo. Cognitive function was correlated with age.

AB - Objectives This study aimed to investigate the effect of trospium chloride on cognitive function in postmenopausal women treated for overactive bladder (OAB). Methods Randomized double-blind placebo-controlled trial conducted from April 2013 to April 2015. Women aged 50 years or older seeking treatment for OAB were randomized to either trospium chloride XR 60 mg daily or placebo. Baseline cognitive function was assessed via Hopkins Verbal Learning Test-Revised (HVLT-R), Mini Mental Status Exam, Mini Mental Status X, Digit Span, Trails A, Trails B, and Epworth Sleepiness Scale. Cognitive function was reassessed at week 1 and week 4. A priori power analysis determined that 21 subjects were needed per group. Results Although 59 women were enrolled and randomized (28 trospium and 31 placebo), 45 completed assessment (21 trospium and 24 placebo). Mean age was 68 years, 78% were white, and 44% had previously taken OAB medication. For the primary outcome, there was no difference in HVLT-R total score between trospium and placebo groups at week 4 (P = 0.29). There were also no differences based on the other cognitive tests. There was a correlation between age and the following week-4 tests: HVLT-R total score (r =-0.3, P = 0.02), HVLT-R total recall subscale (r =-0.4, P = 0.007), Trails A (r = 0.4, P = 0.002), and Trails B (r = 0.4, P = 0.004). A linear regression model found that HVLT-R total score decreased by 0.372 points for each increased year of age. Conclusions In women aged 50 years and older, there were no changes in cognitive function between those taking trospium and placebo. Cognitive function was correlated with age.

KW - anticholinergic

KW - cognitive function

KW - overactive bladder

UR - http://www.scopus.com/inward/record.url?scp=85014689828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014689828&partnerID=8YFLogxK

U2 - 10.1097/SPV.0000000000000374

DO - 10.1097/SPV.0000000000000374

M3 - Article

VL - 23

SP - 118

EP - 123

JO - Female Pelvic Medicine and Reconstructive Surgery

JF - Female Pelvic Medicine and Reconstructive Surgery

SN - 2151-8378

IS - 2

ER -